KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
2.4700
-0.1600 (-6.08%)
At close: 4:15PM EDT
Stock chart is not supported by your current browser
Previous Close2.6300
Open2.6300
Bid2.4700 x 0
Ask2.4800 x 0
Day's Range2.4600 - 2.6300
52 Week Range0.8700 - 4.3500
Volume387,992
Avg. Volume951,193
Market Cap254.442M
Beta (3Y Monthly)3.98
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire3 days ago

    Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO

    TORONTO, June 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019. Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.

  • CNW Group10 days ago

    Khiron Receives Regulatory Approval for Uruguay Acquisition

    TORONTO , June 7, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned. On June 5, 2019 , the Company secured local regulatory approvals in Uruguay for the completion of the Acquisition.

  • PR Newswire11 days ago

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , June 6, 2019 /PRNewswire/ -- Virtual Investor Conferences ...

  • /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/
    PR Newswire14 days ago

    /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/

    TORONTO, June 2, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year
    PR Newswire15 days ago

    Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year

    TORONTO, June 2, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • PR Newswire17 days ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , May 31, 2019 /PRNewswire/ -- Virtual Investor Conferences and KCSA Strategic Communications ...

  • CNW Group17 days ago

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

  • PR Newswire18 days ago

    Khiron Life Sciences to Webcast Live on June 4th at VirtualInvestorConferences.com

    Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com TORONTO , May 30, 2019 /PRNewswire/ ...

  • CNW Group19 days ago

    Khiron Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF

    TORONTO , May 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce today its addition to the MJ ETFMG Alternative Harvest ETF (MJ) (the "Fund"), a fund with approximately US$1.22 billion in assets currently under management. This represents an important development for the Company as it advances its strategy as a Latin American cannabis company with global growth. The Fund tracks the Prime Alternative Harvest Index, designed to measure the performance of companies within the cannabis ecosystem benefiting from global medicinal and recreational cannabis legalization.

  • CNW Group20 days ago

    Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

    TORONTO , May 28, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce that it has closed today its previously announced "bought deal" short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering"). A total of 9,914,150 Common Shares were sold at a price of $2.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $28,751,035 (including the exercise in full of the over-allotment option).

  • CNW Grouplast month

    Khiron Provides Update on Transaction to Acquire NettaGrowth

    TORONTO , May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition.

  • CNW Grouplast month

    Khiron Mails and Files Circular Relating to its Annual General and Special Meeting of Shareholders

    Proxy voting deadline is May 29, 2019 at 11 a.m. ( Toronto time). Board of Directors recommends that Shareholders vote FOR all resolutions. TORONTO , May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "Meeting Materials") to Khiron's shareholders ("Shareholders") in connection with the annual general and special meeting of Shareholders (the "Meeting").

  • CNW Grouplast month

    /C O R R E C T I O N from Source -- Khiron Life Sciences Corp./

    In the news release, Khiron Life Sciences Enters into $25 Million Bought Deal Equity Financing, issued 06-May-2019 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the first paragraph, last sentence, should read "Common Share of $2.90 " rather than "Common Share of $3.00 " as originally issued inadvertently. TORONTO , May 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America , announced today that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, 8,621,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.90 (the "Issue Price") for gross proceeds of $25,000,900 (the "Offering").

  • CNW Group2 months ago

    Khiron Life Sciences Reports 2018 Fiscal Year End Results and Provides Corporate Update

    Khiron Life Sciences Reports 2018 Fiscal Year End Results and Provides Corporate Update

  • Khiron Gets Kuida® Into Another 150 Stores
    PR Newswire2 months ago

    Khiron Gets Kuida® Into Another 150 Stores

    TORONTO, April 30, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has signed a distribution agreements for its Kuida® cosmeceutical brand with Cafam, a leading Colombian drugstore chain. This agreement further expands the brands points of sales In combination with the previous announced distribution arrangements this agreement further expands the brands retail and e-commerce points of sales in Colombia.

  • CNW Group2 months ago

    Khiron Life Sciences Signs Letter of Intent to Establish Medical Cannabis Distribution Agreement for Over 900 pharmacies in Colombia

    TORONTO , April 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with its core operations in Latin America , announced today that the Company has signed an LOI with Copservir Ltda., Colombia's largest pharmacy chain, to distribute Khiron's medical cannabis products across the country. The companies have agreed to initial discounting and commercial fees and will work towards establishing a definitive commercial contract and detailed distribution plan to begin sales in the second half of 2019.